ZURICH (Reuters) - Roche's Tecentriq immunotherapy mixed with chemotherapy won U.S. approval as an initial treatment for a form of lung cancer as the Swiss drugmaker seeks to establish its alternative to drugs from Merck and Bristol-Myers Squibb.
The U.S. Food and Drug Administration approved Tecentriq mixed with Celgene's Abraxane and carboplatin chemotherapy to treat metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations, Roche said on Wednesday.
(Reporting by John Miller; editing by Thomas Seythal)
